253 related articles for article (PubMed ID: 30528563)
1. Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance.
Asnafi AA; Behzad MM; Ghanavat M; Shahjahani M; Saki N
Exp Mol Pathol; 2019 Feb; 106():63-77. PubMed ID: 30528563
[TBL] [Abstract][Full Text] [Related]
2. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
3. Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.
Tang Z; Lu Y; Chen Y; Zhang J; Chen Z; Wang Q
Technol Cancer Res Treat; 2021; 20():15330338211034262. PubMed ID: 34323141
[TBL] [Abstract][Full Text] [Related]
4. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
Cascini C; Chiodoni C
Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract][Full Text] [Related]
6. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin.
Wang SN; Luo S; Liu C; Piao Z; Gou W; Wang Y; Guan W; Li Q; Zou H; Yang ZZ; Wang D; Wang Y; Xu M; Jin H; Xu CX
Mol Ther; 2017 Sep; 25(9):2140-2149. PubMed ID: 28648665
[TBL] [Abstract][Full Text] [Related]
7. Expression of 11β-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: potential role in pathogenesis and as targets for treatments.
Patel P; Hardy R; Sumathi V; Bartle G; Kindblom LG; Grimer R; Bujalska I; Stewart PM; Rabbitt E; Gittoes NJ; Cooper MS
Endocr Relat Cancer; 2012 Aug; 19(4):589-98. PubMed ID: 22719058
[TBL] [Abstract][Full Text] [Related]
8. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
10. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Bhuvaneshwar K; Harris M; Gusev Y; Madhavan S; Iyer R; Vilboux T; Deeken J; Yang E; Shankar S
BMC Cancer; 2019 Apr; 19(1):357. PubMed ID: 30991985
[TBL] [Abstract][Full Text] [Related]
11. Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules.
Poos K; Smida J; Maugg D; Eckstein G; Baumhoer D; Nathrath M; Korsching E
PLoS One; 2015; 10(4):e0123082. PubMed ID: 25848766
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma.
Zhou Y; Liu B; Wang M; Ni J
Pediatr Blood Cancer; 2014 Apr; 61(4):612-7. PubMed ID: 24123836
[TBL] [Abstract][Full Text] [Related]
13. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.
Foley JM; Scholten DJ; Monks NR; Cherba D; Monsma DJ; Davidson P; Dylewski D; Dykema K; Winn ME; Steensma MR
J Transl Med; 2015 Apr; 13():110. PubMed ID: 25889105
[TBL] [Abstract][Full Text] [Related]
14. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
Shi ZW; Wang JL; Zhao N; Guan Y; He W
Cancer Biomark; 2016 Jun; 17(2):249-57. PubMed ID: 27540978
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of gene expression and genomic aberration data in osteosarcoma (OS).
Xiong Y; Wu S; Du Q; Wang A; Wang Z
Cancer Gene Ther; 2015 Nov; 22(11):524-9. PubMed ID: 26427513
[TBL] [Abstract][Full Text] [Related]
18. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J; van Egmond PW; Helder MN; de Menezes RX; Cleton-Jansen AM; Beliën JA; Verheul HM; van Royen BJ; Kaspers GJ; van Beusechem VW
Oncotarget; 2012 Oct; 3(10):1169-81. PubMed ID: 23045411
[TBL] [Abstract][Full Text] [Related]
19. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.
Smida J; Baumhoer D; Rosemann M; Walch A; Bielack S; Poremba C; Remberger K; Korsching E; Scheurlen W; Dierkes C; Burdach S; Jundt G; Atkinson MJ; Nathrath M
Clin Cancer Res; 2010 Aug; 16(16):4256-67. PubMed ID: 20610556
[TBL] [Abstract][Full Text] [Related]
20. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]